NICE Recommends Rhythm’s Imcivree for Obesity and Hunger
The UK’s National Institute of Health and Care Excellence (NICE) has recommended Rhythm Pharmaceuticals’ Imcivree (setmelanotide) for National Health Service (NHS) use in treating obesity linked to three rare genetic disorders.
NICE’s recommendation was supported by results from clinical trials in which Imcivree reduced weight and body mass index in people with obesity caused by pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiencies.
The recommended dosage of Imcivree depends on the patient’s age, ranging from a 0.5 mg daily subcutaneous starting dose for children between six and 11 years old to a 1 mg daily starting dose for older patients.
The list price of Imcivree is more than $2,850 per 10 mg vial. The negotiated price for NHS use was not disclosed.
Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company committed to transforming the care for patients living with rare genetic diseases of obesity. Founded: 2008. Headquarters: Boston, Massachusetts, United States.
July 25, 2022
